Acute renal injury
Conditions
Interventions
Experimental group:Rosalastat + Remove risk factors and incentives + Support treatment
control group:Remove risk factors and incentives + Support treatment
Sponsors
Central Hospital Affiliated to Chongqing University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Voluntary participation and written informed consent; 2. Gender is not limited, age is 16-70 years old; 3. The subject shall meet the following conditions to be diagnosed as PNS with AKI: (1) meet the clinical diagnostic criteria of primary nephrotic syndrome: 1) massive proteinuria (proteinuria >= 3.5g/d), hypoalbuminemia (plasma albumin less than 30g / L), or accompanied by (high) edema and hyperlipidemia; 2) provide renal pathology report] during the hospitalization, the patient shall also meet (2) the diagnostic criteria of AKI (KDIGO): 1) the rise of SCR within 48 hours exceeds 26.5 µ mol/L(0.3 mg/dl); 2) Confirm or speculate that the increase of SCR within 7 days exceeds 50% of the baseline; 3) Urine volume reduction < 0.5 ml / (kg · h), lasting for 6 hours or more (when urine volume change is used as the diagnostic standard alone, it is necessary to exclude urinary tract obstruction or other factors that may lead to urine volume reduction). 4) Be able to follow the study or follow-up procedures.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria shall not be included in the study: 1. Excluding nephrotic syndrome induced by secondary factors: such as genetic diseases, infectious diseases, such as secondary nephrotic syndrome caused by hepatitis B virus infection and allergic purpura, connective tissue diseases, such as systemic lupus erythematosus nephropathy, secondary nephrotic syndrome caused by related drugs, metabolic diseases, such as diabetes, abnormal proteinemia, such as amyloidosis, multiple myeloma, and new biological related nephrotic syndrome. 2. Women who have recent family planning, pregnancy or breastfeeding; 3. Unable to understand the potential risks and benefits of the study, and unable to follow up and evaluate as required; 4. No capacity for civil conduct; 5. History of drug or alcohol abuse; 6. There are any more complicated medical problems that may interfere with the research behavior or lead to increased risk, such as malignant tumor, liver disease (transaminase >= 2 times the normal upper limit), AIDS, viral hepatitis, etc.; 7. Those who are allergic to drugs and are not suitable to use "roxarstat".
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood creatinine;estimated glomerular filtration rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 24-hour urine protein quantification;Blood albumin;TC;TG;LDL-C;HDL-C; | — |
Countries
China
Contacts
Public ContactChen Xingqing
Central Hospital Affiliated to Chongqing University
Outcome results
None listed